← Back to Clinical Trials
Recruiting NCT07685574

NCT07685574 Cholera Control by Case-area Targeted Interventions (CATIs)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07685574
Status Recruiting
Phase
Sponsor International Centre for Diarrhoeal Disease Research, Bangladesh
Condition Cholera
Study Type INTERVENTIONAL
Enrollment 68,400 participants
Start Date 2024-09-05
Primary Completion 2029-09

Eligibility & Interventions

Sex All sexes
Min Age 1 Year
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Cholvax

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 68,400 participants in total. It began in 2024-09-05 with a primary completion date of 2029-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To evaluate the effectiveness of the CATI approach among household contacts in the reduction of cumulative incidence of cholera and explore the genome analysis and immune response of V. cholerae antigen from different hotspots in Dhaka city, cholera cases will be enrolled by rapid diagnostic test (RDT) from the diarrhoeal patients coming to icddr,b Dhaka hospital. Hotspots will be defined as the households (HHs) surrounding the RDT-positive cholera case (around 20-40m radius). The 'Case area targeted interventions' (CATI) will be given by administrating Oral Cholera Vaccine (OCV) with either one dose or two doses of OCV 1 month apart among household contacts (≥1-year age and non-pregnant women) and contacts of the contacts residing in the adjacent HHs. The passive surveillance for cholera will be followed using the icddr,b hospital, and other health facilities. Data on each individual's states of the clusters (e.g., susceptible, exposed, infectious, or recovered) will be tracked throughout the 3 years study follow-up.

Eligibility Criteria

Index case eligibility Inclusion Criteria: 1. Some to severe dehydrated diarrheal patient 2. Provide signed informed consent form Exclusion criteria: 1\. Resident in a ward already covered by OCV since 2015 Vaccination Eligibility Inclusion Criteria: 1. Aged ≥1 year and non-pregnant 2. Meeting the definition of IHC and NHC 3. Provide signed informed consent form Exclusion criteria: 1. History of taking OCV 2. Currently suffering from diarrhea 3. \< 1 year of age 4. Pregnant women (verbally confirmed) 5. Index case

Contact & Investigator

Central Contact

Dr. Fahima Chowdhury, MBBS, MPH, PhD

✉ fchowdhury@icddrb.org

📞 +8801730016458

Frequently Asked Questions

Who can join the NCT07685574 clinical trial?

This trial is open to participants of all sexes, aged 1 Year or older, studying Cholera. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07685574 currently recruiting?

Yes, NCT07685574 is actively recruiting participants. Contact the research team at fchowdhury@icddrb.org for enrollment information.

Where is the NCT07685574 trial being conducted?

This trial is being conducted at Dhaka, Bangladesh.

Who is sponsoring the NCT07685574 clinical trial?

NCT07685574 is sponsored by International Centre for Diarrhoeal Disease Research, Bangladesh. The trial plans to enroll 68,400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology